EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtLeitlinieOpen Access · CC BY 4.0

Anti‐obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline

Alyse Goldberg, Sandro Graca, Jing Liu, Vibhuti Rao, Selma Feldman Witchel, Alexia Pena, Rong Li, Aya Mousa iD, Chau Thien Tay, Loyal Pattuwage, Helena Teede iD, Bulent O Yildiz und 1 weitere

Obesity Reviews · 2024-05 · 25 (5)

DOI: 10.1111/obr.13704 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Obesity Reviews, online erschienen am 14.02.2024. Verfasst von Alyse Goldberg und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Metformin, Polycystic Ovary Syndrome. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Women's Health in Reproductive Life (CRE WHIRL).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review and meta‐analysis evaluated the efficacy of anti‐obesity agents for hormonal, reproductive, metabolic, and psychological outcomes in polycystic ovary syndrome (PCOS) to inform the 2023 update of the International Evidence‐based Guideline on PCOS. We searched Medline, EMBASE, PsycInfo, and CINAHL until July 2022 with a 10‐year limit to focus on newer agents. Eleven trials (545 and 451 participants in intervention and control arms respectively, 12 comparisons) were included. On descriptive analyses, most agents improved anthropometric outcomes; liraglutide, semaglutide and orlistat appeared superior to placebo for anthropometric outcomes. Meta‐analyses were possible for two comparisons (exenatide vs. metformin and orlistat + combined oral contraceptive pill [COCP] vs. COCP alone). On meta‐analysis, no differences were identified between exenatide versus metformin for anthropometric, biochemical hyperandrogenism, and metabolic outcomes, other than lower fasting blood glucose more with metformin than exenatide (MD: 0.10 mmol/L, CI 0.02–0.17, I 2 = 18%, 2 trials). Orlistat + COCP did not improve metabolic outcomes compared with COCP alone (fasting insulin MD: −8.65 pmol/L, −33.55 to 16.26, I 2 = 67%, 2 trials). Published data examining the effects of anti‐obesity agents in women with PCOS are very limited. The role of these agents in PCOS should be a high priority for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsMetforminPolycystic Ovary SyndromeFemaleHumansContraceptives, Oral, CombinedExenatideHypoglycemic AgentsOrlistatPractice Guidelines as Topic

Stichwörter der Autor:innen

GLP1 receptor agonists, meta‐analysisanti‐obesity agentspolycystic ovary syndrome

Substanzen

Anti-Obesity AgentsContraceptives, Oral, CombinedExenatideHypoglycemic AgentsMetforminOrlistat

Autor:innen und Institutionen

  • Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
  • School of Health and Society, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, West Midlands, UK.
  • Department of Research, Northern College of Acupuncture, York, North Yorkshire, UK.
  • NICM Health Research Institute, Western Sydney University, Penrith, New South Wales, Australia.
  • UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Discipline of Paediatrics, Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia.

ORCID-Profile: Aya Mousa, Helena Teede, Carolyn Ee

Förderung

  • Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence in Women's Health in Reproductive Life (CRE WHIRL)

Zitieren

APA

Goldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., Teede, H., Yildiz, B. O., & Ee, C. (2024). Anti‐obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline. Obesity Reviews, 25(5). https://doi.org/10.1111/obr.13704

Vancouver

Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, et al. Anti‐obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline. Obesity Reviews. 2024;25(5). doi:10.1111/obr.13704

BibTeX
@article{Goldberg2024,
  author = {Goldberg, Alyse and Graca, Sandro and Liu, Jing and Rao, Vibhuti and Witchel, Selma Feldman and Pena, Alexia and Li, Rong and Mousa, Aya and Tay, Chau Thien and Pattuwage, Loyal and Teede, Helena and Yildiz, Bulent O and Ee, Carolyn},
  title = {Anti‐obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline},
  journal = {Obesity Reviews},
  year = {2024},
  volume = {25},
  number = {5},
  doi = {10.1111/obr.13704}
}
Kostenlos starten →